5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 0.86▲ | 0.86▲ | 0.88▼ | 1.05▼ | 0.79▲ |
MA10 | 0.87▲ | 0.88▼ | 0.89▼ | 0.94▼ | 0.82▲ |
MA20 | 0.88▼ | 0.90▼ | 0.95▼ | 0.84▲ | 1.36▼ |
MA50 | 0.91▼ | 1.01▼ | 1.01▼ | 0.86▲ | 6.78▼ |
MA100 | 0.98▼ | 0.97▼ | 0.86▲ | 1.45▼ | 13.04▼ |
MA200 | 1.16▼ | 0.85▲ | 0.83▲ | 4.71▼ | 23.41▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.001▲ | 0.003▲ | -0.010▼ | 0.025▲ | 0.369▲ |
RSI | 42.789▼ | 37.925▼ | 41.673▼ | 49.474▼ | 28.731▼ |
STOCH | 19.142▼ | 8.922▼ | 13.019▼ | 28.604 | 13.508▼ |
WILL %R | -71.595 | -74.247 | -88.493▼ | -88.035▼ | -87.017▼ |
CCI | -5.710 | -65.937 | -93.083 | -2.281 | 66.140 |
Thursday, June 12, 2025 05:35 AM
Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, ...
|
Tuesday, June 10, 2025 08:09 AM
The offering is priced at-the-market under Nasdaq rules and is expected to close on or about June 11 subject to customary closing conditions. Separately, D. Boral Capital analyst Jason Kolbert ...
|
Tuesday, June 10, 2025 04:40 AM
Citius Pharmaceuticals (CTXR) raises $6M in a direct offering to fund LYMPHIRâ„¢'s commercial launch and corporate goals.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
13/06/25 | 0.909 | 0.9184 | 0.855 | 0.8746 | 641,766 |
12/06/25 | 0.98 | 1.0191 | 0.85 | 0.92 | 1,041,301 |
11/06/25 | 1.08 | 1.22 | 1.00 | 1.01 | 2,145,677 |
10/06/25 | 0.98 | 1.08 | 0.9119 | 1.055 | 5,704,725 |
09/06/25 | 0.91 | 2.38 | 0.89 | 1.37 | 102,331,008 |
06/06/25 | 0.85 | 0.867 | 0.8101 | 0.851 | 96,353 |
05/06/25 | 0.8887 | 0.92 | 0.8012 | 0.8558 | 106,409 |
04/06/25 | 0.9018 | 0.91 | 0.85 | 0.874 | 99,781 |
03/06/25 | 0.7496 | 0.945 | 0.7372 | 0.865 | 395,084 |
02/06/25 | 0.72 | 0.7698 | 0.6802 | 0.7698 | 264,465 |
|
|
||||
|
|
||||
|
|